BCOR and myelodysplastic syndrome: Taken together, the therapeutic efficiency of decitabine would be optimized if we choose MDS patients with TP53 mutations, NPM1MUT PDNMT3AWT, or BCOR mutations as first-line candidates for the decitabine treatment protocol.